Results of redo liver resections for metastatic colorectal cancer

Kit O.I.; Gevorkyan Yu.A.; Soldatkina N.V.; Dashkov A.V.; Kolesnikov V.E.; Bondarenko O.K.; Khabzhokov E.K.

doi:https://doi.org/10.17116/hirurgia202208145

Kit O.I.

National Medical Oncology Research Center

ORCID: 0000-0003-3061-6108

Gevorkyan Yu.A.

National Medical Research Center for Oncology

Soldatkina N.V.

National Medical Research Center for Oncology

Dashkov A.V.

National Medical Research Center for Oncology

Kolesnikov V.E.

National Medical Research Center for Oncology

Bondarenko O.K.

National Medical Research Centre for Oncology

Khabzhokov E.K.

National Medical Research Centre for Oncology

Results of redo liver resections for metastatic colorectal cancer

Authors:

Kit O.I., Gevorkyan Yu.A., Soldatkina N.V., Dashkov A.V., Kolesnikov V.E., Bondarenko O.K., Khabzhokov E.K.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2022;(8): 45‑52

DOI: 10.17116/hirurgia202208145

Read: 2037 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kit OI, Gevorkyan YuA, Soldatkina NV, Dashkov AV, Kolesnikov VE, Bondarenko OK, Khabzhokov EK. Results of redo liver resections for metastatic colorectal cancer. Pirogov Russian Journal of Surgery. 2022;(8):45‑52. (In Russ.)
https://doi.org/10.17116/hirurgia202208145

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To analyze patients undergoing redo liver resections for metastatic colorectal cancer.

MATERIAL AND METHODS

The study included 14 patients with colorectal cancer who underwent several redo liver resections for metastatic lesions between September 2011 and June 2021. Mean age of patients was 63.5 years. Left-sided colonic G2 adenocarcinoma T4N1-2 prevailed (wild-type KRAS).

RESULTS

Fourteen patients (100%) underwent two liver resections, 7 (50%) — three resections, 1 (7.1%) — four resections. Mean period between the first and the second liver resections was 16.2 months, between the second and the third resections — 9.9 months, between the third and the fourth resections — 5 months. Maximum follow-up period after primary surgery was 9 years and 9 months. Seventy-five percent of patients were alive after 34.2 months, 50% — after 58.9 months. N+ status of colorectal tumor decreased survival while KRAS mutation and synchronous metastatic liver lesions increased survival.

CONCLUSION

Redo liver resections for metastatic colorectal cancer are safe and ensure favorable long-term survival in certain patients.

Keywords:

liver metastases

colorectal cancer

redo liver resections

prognostic factors

results

Authors:

Kit O.I.

National Medical Oncology Research Center

ORCID: 0000-0003-3061-6108

Gevorkyan Yu.A.

National Medical Research Center for Oncology

Soldatkina N.V.

National Medical Research Center for Oncology

Dashkov A.V.

National Medical Research Center for Oncology

Kolesnikov V.E.

National Medical Research Center for Oncology

Bondarenko O.K.

National Medical Research Centre for Oncology

Khabzhokov E.K.

National Medical Research Centre for Oncology

Received:

02.12.2021

Accepted:

16.01.2022

Close metadata

References:

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65:5-29.
Labianca R, Beretta GD, Kildani B. Colon cancer. Crit Rev Oncol Hematol. 2010;74:106-133.
Gevorkyan YA, Kolesnikov VE, Soldatkina NV, Kharagezov DA, Dashkov AV, Kaymakchi DO, Mirzoyan EA, Poluektov SI, Tolmakh RE, Stateshniy ON, Dontsov VA. Minimally invasive surgery in treatment of patients with metastatic colorectal cancer. Yuzhno-Rossiyskiy onkologicheskiy zhurnal. 2020;1(2):22-27. (In Russ.). https://doi.org/10.37748/2687-0533-2020-1-2-3
Ito K, Govindarajan A, Ito H, Fong Y. Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer J. 2010;16:103-110.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065-1075.
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2014;25:1346-1355.
Battula N, Tsapralis D, Mayer D, Isaac J, Muiesan P, Sutcliffe RP. Repeat liver resection for recurrent colorectal metastases: a single-centre, 13-year experience. HPB (Oxford). 2014;16(2):157-163.
Schmidt T, Nienhüser H, Kuna C, Klose J, Strowitzki MJ, Büchler MW, Ulrich A, Schneider M. Prognostic indicators lose their value with repeated resection of colorectal liver metastases. Eur J Surg Oncol. 2018;44(10):1610-1618. Epub 2018 Jul 31. https://doi.org/10.1016/j.ejso.2018.07.051
Oba M, Hasegawa K, Shindoh J, Yamashita S, Sakamoto Y, Makuuchi M, Kokudo N. Survival benefit of repeat resection of successive recurrences after the initial hepatic resection for colorectal liver metastases. Surgery. 2016;159(2):632-640.
Nanji S, Tsang ME, Wei X, Booth CM. Outcomes after repeat hepatic resection for recurrent metastatic colorectal cancer: a population-based study. Am J Surg. 2017;213:1053-1059.
Sponholz S, Schirren M, Baldes N, Oguzhan S, Schirren J. Repeat resection for recurrent pulmonary metastasis of colorectal cancer Langenbeck’s. Arch Surg. 2017;402:77-85.
Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier Ph, Rubbia-Brandt L, Sobrero A, Tabernero J, Teh C, Van Cutsem E, Vauthey JN. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17(10):1225-1239.
Feng Q, Wei Y, Zhu D. Timing of hepatectomy for resectable synchronous colorectal liver metastases: for whom simultaneous resection is more suitable — a meta-analysis. PLoS One. 2014;9(8):e104348.
Chow FCL, Chok KSH. Colorectal liver metastases: An update on multidisciplinary approach. World J Hepatol. 2019;11(2):150-172. PMID: 30820266. https://doi.org/10.4254/wjh.v11.i2.150
Jong MC, Pulitano C, Ribero D. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440-448.
Saiura A, Yamamoto J, Hasegawa K. Liver resection for multiple colorectal liver metastases with surgery up-front approach: bi-institutional analysis of 736 consecutive cases. World J Surg. 2012;36:2171-2178.
Bellier J, De Wolf J, Hebbar M. Repeated resections of hepatic and pulmonary metastases from colorectal cancer provide long-term survival. World J Surg. 2018;42:1171-1179.
Hamady ZZR, Lodge JPA, Welsh FK, Toogood GJ, White A, Jokn T, Rees M. One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Annals of Surgery. 2014;259:3:259(3):543-548.
Ayer N, Ladmabomed ZS, Eggerment AM, Ligerman JN, de Jonge J, Mietfort K, Verboef C. Outcome of Microscopic incomplete resection of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol. 2012;19:1618-1627.
Kwan MY, JaParkbJong LC, Wook KY Sik YS-B, Sik YC Benefits of repeated resections for liver and lung metastases from colorectal cancer. Asian Journal of Surgery. 2020;43(1):102-109.
Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125-135.
Saiura A, Yamamoto J, Koga R, Takahashi Y, Takahashi M, Inoue Y. Favorable outcome after repeat resection for colorectal liver metastases. Ann Surg Oncol. 2014;21(13):4293-4299.
Kit OI, Gevorkyan YA, Soldatkina NV, Timoshkina NN, Kharagezov DA, Kaymakchi DO, Poluektov SI, Dashkov AV, Gudtskova TN. Prognostic factors in colorectal cancer. Koloproktologiya. 2021;20(2):42-49. (In Russ.).
Carpizo DR, D’Angelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Lancet Oncol. 2009;10:801-809.
Kanemitsu Y, Kato T, Komori K, Fukui T, Mitsudomi T. Validation of a nomogram for predicting overall survival after resection of pulmonary metastases from colorectal cancer at a single center. World J Surg. 2010;34:2973-2978.
Elias D, Liberale G, Vernerey D. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol. 2005;12:900-909.
Luo LX, Yu ZY, Huang JW, Wu H. Selecting patients for a second hepatectomy for colorectal metastases: an systemic review and meta-analysis. Eur J Surg Oncol. 2014;40(9):1036-1048.